VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study)

Antonio De Simone, Michele De Pasquale, Carmine De Matteis, Michelangelo Canciello, Michele Manzo, Luigi Sabino, Ferdinando Alfano, Michele Di Mauro, Andrea Campana, Giuseppe De Fabrizio, Dino Franco Vitale, Pietro Turco, Giuseppe Stabile

Research output: Contribution to journalArticle

Abstract

Aims: To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC). Methods and results: Three hundred sixty-three patients were randomized to receive four different pre-treatment protocols: oral amiodarone (group A), oral flecainide (group F), oral amiodarone plus oral verapamil (group A+V), oral flecainide plus oral verapamil (group F+V). Patients who showed an AF recurrence within 3 months were assigned to the alternative group and underwent a second EC after 48 h. During 3 months of follow-up, 89 patients (27.5%) had an AF recurrence. By univariate analysis, verapamil reduced AF recurrences if added to amiodarone or flecainide (from 35% to 20%, P=0.004). Applying Cox proportional hazards regression model, only the younger age, the shorter duration of AF, and the use of verapamil were predictor of maintenance of sinus rhythm after cardioversion. In patients with primary AF recurrence, verapamil addition to group A and F patients, significantly decreased secondary AF recurrence rate as compared to group A+V and F+V patients who stopped the verapamil therapy (68% vs 88%, P=0.03). Conclusions: The addition of verapamil to class IC or III antiarrhythmic drug significantly reduced the AF recurrences, that were more frequent in older patients and in patients with longer lasting AF; moreover, verapamil was effective in reducing the secondary AF recurrences, too.

Original languageEnglish
Pages (from-to)1425-1429
Number of pages5
JournalEuropean Heart Journal
Volume24
Issue number15
DOIs
Publication statusPublished - Aug 2003

Fingerprint

Electric Countershock
Anti-Arrhythmia Agents
Verapamil
Atrial Fibrillation
Recurrence
Flecainide
Amiodarone
Clinical Protocols
Proportional Hazards Models
Maintenance

Keywords

  • Antiarrhythmia agents
  • Cardioversion
  • Fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

De Simone, A., De Pasquale, M., De Matteis, C., Canciello, M., Manzo, M., Sabino, L., ... Stabile, G. (2003). VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study). European Heart Journal, 24(15), 1425-1429. https://doi.org/10.1016/S0195-668X(03)00311-7

VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study). / De Simone, Antonio; De Pasquale, Michele; De Matteis, Carmine; Canciello, Michelangelo; Manzo, Michele; Sabino, Luigi; Alfano, Ferdinando; Di Mauro, Michele; Campana, Andrea; De Fabrizio, Giuseppe; Vitale, Dino Franco; Turco, Pietro; Stabile, Giuseppe.

In: European Heart Journal, Vol. 24, No. 15, 08.2003, p. 1425-1429.

Research output: Contribution to journalArticle

De Simone, A, De Pasquale, M, De Matteis, C, Canciello, M, Manzo, M, Sabino, L, Alfano, F, Di Mauro, M, Campana, A, De Fabrizio, G, Vitale, DF, Turco, P & Stabile, G 2003, 'VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study)', European Heart Journal, vol. 24, no. 15, pp. 1425-1429. https://doi.org/10.1016/S0195-668X(03)00311-7
De Simone, Antonio ; De Pasquale, Michele ; De Matteis, Carmine ; Canciello, Michelangelo ; Manzo, Michele ; Sabino, Luigi ; Alfano, Ferdinando ; Di Mauro, Michele ; Campana, Andrea ; De Fabrizio, Giuseppe ; Vitale, Dino Franco ; Turco, Pietro ; Stabile, Giuseppe. / VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study). In: European Heart Journal. 2003 ; Vol. 24, No. 15. pp. 1425-1429.
@article{d3432bcb08d54c53ab627052d75671d4,
title = "VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study)",
abstract = "Aims: To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC). Methods and results: Three hundred sixty-three patients were randomized to receive four different pre-treatment protocols: oral amiodarone (group A), oral flecainide (group F), oral amiodarone plus oral verapamil (group A+V), oral flecainide plus oral verapamil (group F+V). Patients who showed an AF recurrence within 3 months were assigned to the alternative group and underwent a second EC after 48 h. During 3 months of follow-up, 89 patients (27.5{\%}) had an AF recurrence. By univariate analysis, verapamil reduced AF recurrences if added to amiodarone or flecainide (from 35{\%} to 20{\%}, P=0.004). Applying Cox proportional hazards regression model, only the younger age, the shorter duration of AF, and the use of verapamil were predictor of maintenance of sinus rhythm after cardioversion. In patients with primary AF recurrence, verapamil addition to group A and F patients, significantly decreased secondary AF recurrence rate as compared to group A+V and F+V patients who stopped the verapamil therapy (68{\%} vs 88{\%}, P=0.03). Conclusions: The addition of verapamil to class IC or III antiarrhythmic drug significantly reduced the AF recurrences, that were more frequent in older patients and in patients with longer lasting AF; moreover, verapamil was effective in reducing the secondary AF recurrences, too.",
keywords = "Antiarrhythmia agents, Cardioversion, Fibrillation",
author = "{De Simone}, Antonio and {De Pasquale}, Michele and {De Matteis}, Carmine and Michelangelo Canciello and Michele Manzo and Luigi Sabino and Ferdinando Alfano and {Di Mauro}, Michele and Andrea Campana and {De Fabrizio}, Giuseppe and Vitale, {Dino Franco} and Pietro Turco and Giuseppe Stabile",
year = "2003",
month = "8",
doi = "10.1016/S0195-668X(03)00311-7",
language = "English",
volume = "24",
pages = "1425--1429",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study)

AU - De Simone, Antonio

AU - De Pasquale, Michele

AU - De Matteis, Carmine

AU - Canciello, Michelangelo

AU - Manzo, Michele

AU - Sabino, Luigi

AU - Alfano, Ferdinando

AU - Di Mauro, Michele

AU - Campana, Andrea

AU - De Fabrizio, Giuseppe

AU - Vitale, Dino Franco

AU - Turco, Pietro

AU - Stabile, Giuseppe

PY - 2003/8

Y1 - 2003/8

N2 - Aims: To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC). Methods and results: Three hundred sixty-three patients were randomized to receive four different pre-treatment protocols: oral amiodarone (group A), oral flecainide (group F), oral amiodarone plus oral verapamil (group A+V), oral flecainide plus oral verapamil (group F+V). Patients who showed an AF recurrence within 3 months were assigned to the alternative group and underwent a second EC after 48 h. During 3 months of follow-up, 89 patients (27.5%) had an AF recurrence. By univariate analysis, verapamil reduced AF recurrences if added to amiodarone or flecainide (from 35% to 20%, P=0.004). Applying Cox proportional hazards regression model, only the younger age, the shorter duration of AF, and the use of verapamil were predictor of maintenance of sinus rhythm after cardioversion. In patients with primary AF recurrence, verapamil addition to group A and F patients, significantly decreased secondary AF recurrence rate as compared to group A+V and F+V patients who stopped the verapamil therapy (68% vs 88%, P=0.03). Conclusions: The addition of verapamil to class IC or III antiarrhythmic drug significantly reduced the AF recurrences, that were more frequent in older patients and in patients with longer lasting AF; moreover, verapamil was effective in reducing the secondary AF recurrences, too.

AB - Aims: To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC). Methods and results: Three hundred sixty-three patients were randomized to receive four different pre-treatment protocols: oral amiodarone (group A), oral flecainide (group F), oral amiodarone plus oral verapamil (group A+V), oral flecainide plus oral verapamil (group F+V). Patients who showed an AF recurrence within 3 months were assigned to the alternative group and underwent a second EC after 48 h. During 3 months of follow-up, 89 patients (27.5%) had an AF recurrence. By univariate analysis, verapamil reduced AF recurrences if added to amiodarone or flecainide (from 35% to 20%, P=0.004). Applying Cox proportional hazards regression model, only the younger age, the shorter duration of AF, and the use of verapamil were predictor of maintenance of sinus rhythm after cardioversion. In patients with primary AF recurrence, verapamil addition to group A and F patients, significantly decreased secondary AF recurrence rate as compared to group A+V and F+V patients who stopped the verapamil therapy (68% vs 88%, P=0.03). Conclusions: The addition of verapamil to class IC or III antiarrhythmic drug significantly reduced the AF recurrences, that were more frequent in older patients and in patients with longer lasting AF; moreover, verapamil was effective in reducing the secondary AF recurrences, too.

KW - Antiarrhythmia agents

KW - Cardioversion

KW - Fibrillation

UR - http://www.scopus.com/inward/record.url?scp=0042066341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042066341&partnerID=8YFLogxK

U2 - 10.1016/S0195-668X(03)00311-7

DO - 10.1016/S0195-668X(03)00311-7

M3 - Article

C2 - 12909071

AN - SCOPUS:0042066341

VL - 24

SP - 1425

EP - 1429

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 15

ER -